Fund+ invests in innovative life sciences companies, primarily focusing on therapeutics, diagnostics, and medical devices. They target companies seeking Series A or B financing that have already achieved Proof of Concept (POC). The fund aims to generate both attractive financial returns and a positive societal impact, contributing to a sustainable improvement in the biotech ecosystem. Fund+ operates as an open-ended fund for long-term equity investments, with a particular emphasis on companies within Belgium. Their mission is to create sustainable shareholder value, support the development of a leadership position within the Life Sciences sector, and generate a tangible, beneficial societal impact. The firm's origin stems from the collaboration between the private foundation Désiré Collen and the non-profit organization Life Sciences Research Partners in May 2015. Fund+'s investment approach is guided by a commitment to long-term vision and societal values, shared by its diverse investor base, including high net worth individuals, family offices, and governmental agencies. They typically invest between 5 and 15 million euros per company, spread across various milestones. The firm is legally structured as a Belgian Naamloze Vennootschap/Société Anonyme (NV/SA) and is based in the Groot Begijnhof of Leuven, a designated World Heritage Site.
Preferred startup development maturity for initial funding deployment.
therapeutics, diagnostics, medical devices
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...